Actis Generics Private Limited

Board approved slump sale of API business (13.54% of FY26 revenue) to wholly owned subsidiary RPGAP for Rs 33.55 crore. RPGAP to raise Rs 243.33 crore from India Life Sciences Fund and Vistaject Fund